Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

NCT05566223 is registered in ClinicalTrials.gov with Intima Bioscience, Inc. as lead sponsor.

NCT NCT05566223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05566223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Lead sponsor
Intima Bioscience, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
February 28, 2023
Completion date
November 30, 2027
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, carcinoma, non-small-cell lung, large cell lung cancer, metastatic non small cell lung cancer, squamous cell lung cancer, stage iv non-small cell lung cancer